Loading...

Natus Medical

Nasdaq:BABY
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BABY
Nasdaq
$848M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
  • Natus Medical has significant price volatility in the past 3 months.
BABY Share Price and Events
7 Day Returns
4.8%
NasdaqGS:BABY
-1.6%
US Medical Equipment
0.9%
US Market
1 Year Returns
-25.5%
NasdaqGS:BABY
15.6%
US Medical Equipment
9.6%
US Market
BABY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Natus Medical (BABY) 4.8% -2.3% -25.6% -25.5% -21% 3.5%
US Medical Equipment -1.6% -4.3% 4.1% 15.6% 51.6% 93.5%
US Market 0.9% 4.6% 10.9% 9.6% 39% 47.2%
1 Year Return vs Industry and Market
  • BABY underperformed the Medical Equipment industry which returned 15.6% over the past year.
  • BABY underperformed the Market in United States of America which returned 9.6% over the past year.
Price Volatility
BABY
Industry
5yr Volatility vs Market

Value

 Is Natus Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Natus Medical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Natus Medical.

NasdaqGS:BABY Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.8%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:BABY
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.93 (1 + (1- 21%) (12.32%))
1.014
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.01
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.014 * 5.96%)
8.77%

Discounted Cash Flow Calculation for NasdaqGS:BABY using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Natus Medical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:BABY DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.77%)
2019 16.48 Est @ -38.93% 15.15
2020 12.12 Est @ -26.43% 10.25
2021 9.98 Est @ -17.68% 7.75
2022 8.83 Est @ -11.56% 6.30
2023 8.18 Est @ -7.27% 5.37
2024 7.83 Est @ -4.27% 4.73
2025 7.66 Est @ -2.17% 4.25
2026 7.61 Est @ -0.7% 3.88
2027 7.64 Est @ 0.33% 3.58
2028 7.72 Est @ 1.05% 3.33
Present value of next 10 years cash flows $64.60
NasdaqGS:BABY DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $7.72 × (1 + 2.73%) ÷ (8.77% – 2.73%)
$131.18
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $131.18 ÷ (1 + 8.77%)10
$56.58
NasdaqGS:BABY Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $64.60 + $56.58
$121.19
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $121.19 / 33.66
$3.6
NasdaqGS:BABY Discount to Share Price
Calculation Result
Value per share (USD) From above. $3.60
Current discount Discount to share price of $25.19
= -1 x ($25.19 - $3.60) / $3.60
-599.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Natus Medical is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Natus Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Natus Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:BABY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.69
NasdaqGS:BABY Share Price ** NasdaqGS (2019-04-25) in USD $25.19
United States of America Medical Equipment Industry PE Ratio Median Figure of 63 Publicly-Listed Medical Equipment Companies 39.57x
United States of America Market PE Ratio Median Figure of 3,081 Publicly-Listed Companies 18.28x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Natus Medical.

NasdaqGS:BABY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:BABY Share Price ÷ EPS (both in USD)

= 25.19 ÷ -0.69

-36.37x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Natus Medical is loss making, we can't compare its value to the US Medical Equipment industry average.
  • Natus Medical is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Natus Medical's expected growth come at a high price?
Raw Data
NasdaqGS:BABY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -36.37x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
106.2%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 54 Publicly-Listed Medical Equipment Companies 2.35x
United States of America Market PEG Ratio Median Figure of 2,113 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Natus Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Natus Medical's assets?
Raw Data
NasdaqGS:BABY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $11.89
NasdaqGS:BABY Share Price * NasdaqGS (2019-04-25) in USD $25.19
United States of America Medical Equipment Industry PB Ratio Median Figure of 184 Publicly-Listed Medical Equipment Companies 4.25x
United States of America Market PB Ratio Median Figure of 5,185 Publicly-Listed Companies 1.92x
NasdaqGS:BABY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:BABY Share Price ÷ Book Value per Share (both in USD)

= 25.19 ÷ 11.89

2.12x

* Primary Listing of Natus Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Natus Medical is good value based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Natus Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Natus Medical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Natus Medical expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
106.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Natus Medical expected to grow at an attractive rate?
  • Natus Medical's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Natus Medical's earnings growth is expected to exceed the United States of America market average.
  • Natus Medical's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:BABY Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:BABY Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 106.2%
NasdaqGS:BABY Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts -2.2%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 20.8%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:BABY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:BABY Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 515 48 1
2019-12-31 499 29 2
NasdaqGS:BABY Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 531 33 -23
2018-09-30 521 24 -18
2018-06-30 513 21 -21
2018-03-31 505 25 -24
2017-12-31 501 20 -20
2017-09-30 477 18 -3
2017-06-30 445 50 19
2017-03-31 419 55 34
2016-12-31 382 73 43
2016-09-30 374 70 41
2016-06-30 378 50 39
2016-03-31 374 42 38

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Natus Medical's earnings are expected to grow significantly at over 20% yearly.
  • Natus Medical's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:BABY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Natus Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:BABY Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 1.41 1.41 1.41 1.00
2019-12-31 0.86 0.86 0.86 1.00
NasdaqGS:BABY Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.69
2018-09-30 -0.56
2018-06-30 -0.65
2018-03-31 -0.73
2017-12-31 -0.62
2017-09-30 -0.09
2017-06-30 0.58
2017-03-31 1.06
2016-12-31 1.31
2016-09-30 1.26
2016-06-30 1.19
2016-03-31 1.17

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Natus Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Natus Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Natus Medical has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Natus Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Natus Medical's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Natus Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Natus Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Natus Medical's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Natus Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Natus Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:BABY Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 530.89 -22.94 207.28 61.48
2018-09-30 521.34 -18.40 207.42 59.91
2018-06-30 513.34 -21.33 208.29 56.42
2018-03-31 504.92 -23.79 205.68 54.51
2017-12-31 500.97 -20.29 200.59 51.82
2017-09-30 477.23 -2.97 189.52 48.95
2017-06-30 445.49 18.86 172.22 45.00
2017-03-31 419.22 34.40 150.87 38.39
2016-12-31 381.89 42.59 135.71 33.44
2016-09-30 374.14 40.91 134.26 31.16
2016-06-30 377.82 38.53 134.22 31.17
2016-03-31 373.80 37.87 134.82 31.38
2015-12-31 375.87 37.92 134.04 30.43
2015-09-30 369.93 39.82 132.41 29.70
2015-06-30 365.22 36.71 132.74 29.46
2015-03-31 359.61 34.32 131.11 29.78
2014-12-31 355.83 32.48 131.17 30.10
2014-09-30 352.46 31.44 122.31 30.01
2014-06-30 347.98 29.90 123.51 30.08
2014-03-31 343.90 26.46 125.65 31.04
2013-12-31 344.11 23.15 126.52 30.79
2013-09-30 344.30 18.77 126.24 32.46
2013-06-30 339.92 10.73 132.80 33.44
2013-03-31 318.71 7.04 125.66 31.43
2012-12-31 292.28 3.82 116.27 29.97
2012-09-30 265.81 -17.93 114.79 28.85
2012-06-30 236.13 -16.03 96.35 26.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Natus Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Natus Medical has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Natus Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Natus Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Natus Medical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Natus Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Natus Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Natus Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Natus Medical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Natus Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Natus Medical Company Filings, last reported 3 months ago.

NasdaqGS:BABY Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 398.44 104.47 56.37
2018-09-30 409.96 114.43 54.44
2018-06-30 407.53 119.38 54.91
2018-03-31 416.83 129.33 64.47
2017-12-31 422.10 154.28 88.95
2017-09-30 425.02 154.24 132.41
2017-06-30 426.49 109.50 80.30
2017-03-31 420.41 149.89 112.86
2016-12-31 417.37 140.00 247.57
2016-09-30 409.39 0.00 106.50
2016-06-30 396.22 10.00 96.28
2016-03-31 392.35 0.00 81.29
2015-12-31 390.71 0.00 82.47
2015-09-30 380.76 0.00 82.20
2015-06-30 373.77 0.00 73.24
2015-03-31 358.57 0.00 67.00
2014-12-31 352.72 0.00 66.56
2014-09-30 331.83 8.00 57.81
2014-06-30 330.41 16.41 56.02
2014-03-31 319.82 32.94 59.59
2013-12-31 308.21 38.02 56.11
2013-09-30 288.71 48.06 44.19
2013-06-30 279.36 50.56 28.91
2013-03-31 272.93 52.71 24.35
2012-12-31 268.75 32.86 23.06
2012-09-30 259.86 31.00 19.50
2012-06-30 259.27 31.80 16.96
  • Natus Medical's level of debt (26.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (12.3% vs 26.2% today).
  • Debt is well covered by operating cash flow (31.6%, greater than 20% of total debt).
  • Natus Medical is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess Natus Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Natus Medical has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Natus Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Natus Medical dividends.
If you bought $2,000 of Natus Medical shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Natus Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Natus Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:BABY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:BABY Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Natus Medical has not reported any payouts.
  • Unable to verify if Natus Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Natus Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Natus Medical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Natus Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Natus Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Natus Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Natus Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jonathan Kennedy
COMPENSATION $1,609,178
AGE 47
TENURE AS CEO 0.8 years
CEO Bio

Mr. Jonathan A. Kennedy, CPA has been the President, Chief Executive Officer and a Director at Natus Medical Incorporated since July 11, 2018. Mr. Kennedy was the Chief Financial Officer at Natus Medical Inc. since April 8, 2013 until July 11, 2018 and was its General Manager of Newborn Care since April 17, 2017. He joined Natus in April 2013. Mr. Kennedy served as an Executive Vice President at Natus Medical Inc. since September 2016 until July 11, 2018 and served as its Senior Vice President of Finance/Senior Vice President since April 8, 2013. Mr. Kennedy served as the Chief Financial Officer and Senior Vice President of Intersil Corporation from April 2009 to March 31, 2013 and its Principal Accounting Officer until March 31, 2013. Mr. Kennedy served as Interim Chief Financial Officer of Intersil Corp. from December 3, 2008 to April 2009. He joined Intersil in 2004 as Director of Finance and served as its Corporate Controller since 2005. He was Advisor of Intersil Corporation from March 31, 2013 to April 05, 2013. He held management roles in Finance and IT with Alcon Inc. and Harris Corporation. He is a Certified Public Accountant. He has been a Director of IRadimed Corporation since June 28, 2016. Mr. Kennedy holds a Bachelor of Science degree in Business Administration and a Master of Science degree in Accounting from the University of Central Florida.

CEO Compensation
  • Jonathan's compensation has been consistent with company performance over the past year.
  • Jonathan's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Natus Medical management team in years:

0.3
Average Tenure
51.5
Average Age
  • The average tenure for the Natus Medical management team is less than 2 years, this suggests a new team.
Management Team

Jonathan Kennedy

TITLE
President
COMPENSATION
$2M
AGE
47
TENURE
0.8 yrs

D. Chung

TITLE
VP of Quality
COMPENSATION
$636K
AGE
54
TENURE
0.3 yrs

Austin Noll

TITLE
Executive VP & Chief Commercial Officer
COMPENSATION
$933K
AGE
51
TENURE
0.3 yrs

Benjamin Davies

TITLE
Executive VP & CFO
AGE
52
TENURE
0.5 yrs

Seán Langan

TITLE
Vice President Global Operations
TENURE
0.3 yrs

Ivan Pandiyan

TITLE
Vice President of Global Research & Development
TENURE
0.3 yrs

Bill Hill

TITLE
General Counsel
TENURE
0.3 yrs

Martin Woodrow

TITLE
Vice President of Human Resources
TENURE
2.1 yrs
Board of Directors Tenure

Average tenure and age of the Natus Medical board of directors in years:

0.8
Average Tenure
60.5
Average Age
  • The average tenure for the Natus Medical board of directors is less than 3 years, this suggests a new board.
Board of Directors

Barbara Paul

TITLE
Chairperson
COMPENSATION
$227K
AGE
64
TENURE
1.3 yrs

Jonathan Kennedy

TITLE
President
COMPENSATION
$2M
AGE
47
TENURE
0.8 yrs

Ken Ludlum

TITLE
Director
COMPENSATION
$250K
AGE
64
TENURE
16.4 yrs

Lisa Heine

TITLE
Independent Director
AGE
54
TENURE
0.8 yrs

Alice Schroeder

TITLE
Independent Director
AGE
61
TENURE
0.2 yrs

Tom Sullivan

TITLE
Independent Director
AGE
54
TENURE
0.2 yrs

Bob Gunst

TITLE
Director
COMPENSATION
$315K
AGE
70
TENURE
14.8 yrs

Joshua Levine

TITLE
Independent Director
AGE
60
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • Natus Medical insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
11. Mar 19 Buy Lisa Heine Individual 07. Mar 19 07. Mar 19 100 $27.18 $2,718
05. Mar 19 Sell Robert Gunst Individual 01. Mar 19 04. Mar 19 -8,304 $28.50 $-233,251
03. Dec 18 Sell Kenneth Ludlum Individual 26. Oct 18 29. Nov 18 -30,000 $34.93 $-930,500
20. Nov 18 Sell Robert Gunst Individual 19. Nov 18 19. Nov 18 -14,750 $33.54 $-494,715
31. Aug 18 Sell Jonathan Kennedy Individual 29. Aug 18 30. Aug 18 -16,255 $36.96 $-599,075
31. Jul 18 Sell Robert Gunst Individual 27. Jul 18 31. Jul 18 -12,840 $36.05 $-445,038
X
Management checks
We assess Natus Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Natus Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

If You Had Bought Natus Medical (NASDAQ:BABY) Stock A Year Ago, You'd Be Sitting On A 29% Loss, Today

Unfortunately the Natus Medical Incorporated (NASDAQ:BABY) share price slid 29% over twelve months. … Shareholders have had an even rougher run lately, with the share price down 24% in the last 90 days. … By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

Simply Wall St -

Natus Medical Incorporated’s (NASDAQ:BABY) Investment Returns Are Lagging Its Industry

In particular, we'll consider its Return On Capital Employed (ROCE), as that can give us insight into how profitably the company is able to employ capital in its business. … Understanding Return On Capital Employed (ROCE). … ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business.

Simply Wall St -

How Financially Strong Is Natus Medical Incorporated (NASDAQ:BABY)?

While small-cap stocks, such as Natus Medical Incorporated (NASDAQ:BABY) with its market cap of US$1.2b, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Companies operating in the Medical Equipment industry,.

Simply Wall St -

What Should Investors Know About Natus Medical Incorporated's (NASDAQ:BABY) Return On Capital?

and want a simplistic look at the return on Natus Medical Incorporated (NASDAQ:BABY) stock. … Therefore, looking at how efficiently Natus Medical is able to use capital to create earnings will help us understand your potential return. … Investors use many different metrics but the analysis below focuses on return on capital employed (ROCE).

Simply Wall St -

Are Natus Medical Incorporated's (NASDAQ:BABY) Interest Costs Too High?

Investors are always looking for growth in small-cap stocks like Natus Medical Incorporated (NASDAQ:BABY), with a market cap of US$1.18b. … However, an important fact which most ignore is: how financially healthy is the business? … Medical Equipment companies,.

Simply Wall St -

Have Investors Priced In Natus Medical Incorporated's (NASDAQ:BABY) Growth?

Natus Medical Incorporated (NASDAQ:BABY), a medical equipment company based in United States,. … Today I will analyse the most recent data on Natus Medical’s outlook and valuation to see if the opportunity still exists … View out our latest analysis for Natus Medical

Simply Wall St -

What Does Natus Medical Incorporated's (NASDAQ:BABY) Share Price Indicate?

I find that Natus Medical’s ratio of 2.35x is trading slightly below its industry peers’ ratio of 3.94x, which means if you buy Natus Medical today, you’d be paying a relatively reasonable price for it. … And if you believe Natus Medical should be trading in this range, then there isn’t much room for the share price grow beyond what it’s currently trading. … In addition to this, it seems like Natus Medical’s share price is quite stable, which could mean there may be less chances to buy low in the future now that it’s fairly valued.

Simply Wall St -

Company Info

Description

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing screening products; diagnostic hearing assessment products to screen for/or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems; balance and mobility systems to diagnose and assist in treating balance disorders; and thermoregulation products to control the incubators and warmers. Additionally, it offers jaundice management products; brain injury products; NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); essential products used in the everyday operation of NICU; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation and sound rooms to hearing and balance care professionals. It serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Pleasanton, California.

Details
Name: Natus Medical Incorporated
BABY
Exchange: NasdaqGS
Founded: 1987
$847,967,594
33,662,866
Website: http://www.natus.com
Address: Natus Medical Incorporated
6701 Koll Center Parkway,
Suite 120,
Pleasanton,
California, 94566,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS BABY Common Stock Nasdaq Global Select US USD 20. Jul 2001
DB NM4 Common Stock Deutsche Boerse AG DE EUR 20. Jul 2001
Number of employees
Current staff
Staff numbers
1,729
Natus Medical employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/26 01:41
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/02/14
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.